Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reply to A. Rizzo et al

Jennifer Gile1, Amina Jatoi1, Wen Wee Ma1

  • 1Jennifer Gile, MD, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Amina Jatoi, MD, and Wen Wee Ma, MD, Division of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN; Mitesh Borad, MD, Division of Oncology, Department of Medicine, Mayo Clinic, Scottsdale, AZ; and Nguyen H. Tran, MD, Division of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN.

JCO Precision Oncology
|March 16, 2022
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response.

JCO precision oncology·2026
Same author

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Cellular Therapies in Solid Tumors: Are We Ready for Primetime?

JCO oncology practice·2026
Same author

Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience.

JCO precision oncology·2026
Same author

Intimate Demographic Questions: Are Patients With Cancer Comfortable Answering?

The American journal of hospice & palliative care·2026
Same author

Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer.

JCO precision oncology·2026
Same journal

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.

JCO precision oncology·2026
Same journal

Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis.

JCO precision oncology·2026
Same journal

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

JCO precision oncology·2026
Same journal

Multimodal Spatiotemporal Signature Integrating Pathomics and Longitudinal Magnetic Resonance Imaging Predicts Response to Neoadjuvant Therapy and Prognosis in Rectal Cancer.

JCO precision oncology·2026
Same journal

Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies.

JCO precision oncology·2026
Same journal

Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis.

JCO precision oncology·2026
See all related articles